Our strategy to create value
Summit’s business model targets the signing of multiple early-stage licensing and technology deals to:
i) Generate upfront cash payments
ii) Remove future development costs
iii) Retain valuable upside potential through development milestones and sales royalties.
We believe our Seglin™ technology platform underpins our early-stage deal strategy because it has multiple opportunities for new commercial deals in a number of major therapy areas.
Our business model aims to mitigate the financial risks traditionally associated with biotechnology companies who advance only a few drug programmes through to the late-stages of clinical development, resulting in extended development times and rising costs, before entering into licensing agreements.
Summit has demonstrated a track record of technical achievement and commercial delivery from within its drug portfolio and over the last two years has established a number of programme licensing agreements.
Barry Price, PhD
Executive Chairman
